Colon cancer screening doubles with new e-health record use

March 04, 2013

SEATTLE--Researchers used electronic health records to identify Group Health patients who weren't screened regularly for cancer of the colon and rectum--and to encourage them to be screened. This centralized, automated approach doubled these patients' rates of on-time screening--and saved health costs--over two years. The March 5 Annals of Internal Medicine published the randomized controlled trial.

"Screening for colorectal cancer can save lives, by finding cancer early--and even by detecting polyps before cancer starts," said study leader Beverly B. Green, MD, MPH. "But screening can't help if you don't do it--and do it regularly," added Dr. Green, a family physician at Group Health and an affiliate investigator at Group Health Research Institute.

More than one in 20 Americans will develop colorectal cancer, which is second only to lung cancer in causing deaths from cancer, Dr. Green said. Screening for colorectal cancer is strongly recommended for everyone age 50 to 75 years, but almost half of Americans do not get screened regularly--far below the screening rates for cervical and breast cancer.

"It's important to find ways to ensure that more people are screened for colorectal cancer--and keep being screened regularly," Dr. Green said. "I've seen patients die from this cancer. So I was thrilled to find that our intervention doubled screening rates and kept them up to date regularly over two years in people who hadn't been getting regular screening."

The SOS (Systems of Support to Increase Colorectal Cancer Screening) trial started by identifying 4,675 Group Health patients, age 50 to 73, who weren't up to date for colorectal cancer screening. Then they were randomly assigned to one of four stepped groups:Each step of the SOS intervention raised the percentage of patients who were current for colorectal screening for both years: 26 percent for usual, 51 percent for automated, 57 percent for assisted, and 65 percent for navigated care.

The two-year costs of the automated intervention plus the screening were actually $89 lower than if the patients had received only usual care. The reason: compared with patients who received usual care, more of those in the automated care group happened to choose FOBT instead of sigmoidoscopy or colonoscopy. And the kit costs much less than the procedures do.

"Traditionally, the onus has been on each primary-care doctor to encourage their patients to get health screening tests on schedule," Dr. Green said. Group Health pioneered using a centralized registry to remind women to be screened regularly for breast cancer. "We borrowed that approach and applied it to colorectal cancer," she added. "We empowered patients to do testing on time, by giving them options, or sending them a FOBT kit by default if no choice was made."

What's next? "We plan to test whether improved adherence persists for more than two years," she said. This is particularly important for patients who choose FOBT, because it should be repeated every year. "We are also testing this intervention in 'safety-net' clinics, which serve low-income people," Dr. Green added. More of those clinics now have electronic health records and can now leverage these to provide population-based care, similar to Group Health and Kaiser Permanente.
-end-
The SOS trial was supported by grant R01CA121125 from the National Cancer Institute of the National Institutes of Health.

Dr. Green's co-authors at Group Health Research Institute were Assistant Investigator Jessica Chubak, PhD, MBHL, Senior Biostatistician Melissa L. Anderson, MS, and Analyst Programmer Sharon Fuller. Dr. Green has a joint appointment as an assistant clinical professor at the University of Washington School of Medicine, and Dr. Chubak is also at the University of Washington School of Public Health. Their other co-authors were Ching-Yun Wang, PhD, of the Fred Hutchinson Cancer Research Center, in Seattle; Richard T. Meenan, PhD, of the Kaiser Permanente Center for Health Research, in Portland, OR; and Sally W. Vernon, PhD, of The University of Texas Health Science Center at Houston.

Second study in same issue

Other Group Health researchers published a different study of colorectal screening in the same issue of the Annals of Internal Medicine: Diana S.M. Buist, PhD, and Carolyn M. Rutter, PhD, senior investigators; Jessica Chubak, PhD, an assistant investigator; Aruna Kamineni, PhD, a research associate; Eric Johnson, MS, a biostatistician; and Joseph Webster, a programmer/analyst.

In people of average risk at four HMO Research Network sites, including Group Health, they found that screening colonoscopy was associated with reduced risk of newly diagnosed late-stage cancers for both left- and right-sided colorectal cancers. Screening sigmoidoscopy was associated with a reduced risk of left-sided, but not right-sided, late-stage colorectal cancers. (Cancers differ depending on whether they are on the left or right side of the bowel.)

They published with colleagues at the University of Pennsylvania Perelman School of Medicine, in Philadelphia; the Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute, in Boston; the University of Massachusetts Medical School, in Worcester; the University of Washington School of Public Health, in Seattle; the National Cancer Institute, in Bethesda, MD; Meyers Primary Care Institute/Reliant Medical Group, in Worcester; HealthPartners Health System, in MN; Marshfield Clinic Research Foundation, in WI; Kaiser Permanente Northwest, in Portland, OR; Kaiser Permanente Division of Research, Oakland, CA; and Kaiser Permanente Hawaii, in Honolulu.

Annals of Internal Medicine

Established in 1927 by the American College of Physicians (ACP), Annals of Internal Medicine is the premier internal medicine journal. Annals of Internal Medicine's mission is to promote excellence in medicine, enable physicians and other health care professionals to be well informed members of the medical community and society, advance standards in the conduct and reporting of medical research, and contribute to improving the health of people worldwide. To achieve this mission, the journal publishes a wide variety of original research, review articles, practice guidelines, and commentary relevant to clinical practice, health care delivery, public health, health care policy, medical education, ethics, and research methodology. In addition, the journal publishes personal narratives that convey the feeling and the art of medicine.

HMO Research Network

The HMO Research Network includes 19 research centers, each associated with a health care delivery system. Researchers at the centers collaborate on multi-site studies in real-world health care settings across the United States and in Israel. With access to information on more than 16 million ethnically and geographically diverse patients, these researchers are finding solutions for common and rare health problems. Since 1994, the Network has been answering pressing questions about keeping people healthy and delivering effective care.Group Health Research Institute

Group Health Research Institute does practical research that helps people like you and your family stay healthy. The Institute is the research arm of Seattle-based Group Health Cooperative, a consumer-governed, nonprofit health care system. Founded in 1947, Group Health Cooperative coordinates health care and coverage. Group Health Research Institute changed its name from Group Health Center for Health Studies in 2009. Since 1983, the Institute has conducted nonproprietary public-interest research on preventing, diagnosing, and treating major health problems. Government and private research grants provide its main funding.

Group Health Research Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.